168 related articles for article (PubMed ID: 21791942)
41. Concurrent radiotherapy with temozolomide vs. concurrent radiotherapy with a cisplatinum-based polychemotherapy regimen : Acute toxicity in pediatric high-grade glioma patients.
Seidel C; von Bueren AO; Bojko S; Hoffmann M; Pietsch T; Gielen GH; Warmuth-Metz M; Bison B; Kortmann RD; Kramm CM
Strahlenther Onkol; 2018 Mar; 194(3):215-224. PubMed ID: 29022050
[TBL] [Abstract][Full Text] [Related]
42. Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas.
Balmaceda C; Peereboom D; Pannullo S; Cheung YK; Fisher PG; Alavi J; Sisti M; Chen J; Fine RL
Cancer; 2008 Mar; 112(5):1139-46. PubMed ID: 18246536
[TBL] [Abstract][Full Text] [Related]
43. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
Wick W; Hartmann C; Engel C; Stoffels M; Felsberg J; Stockhammer F; Sabel MC; Koeppen S; Ketter R; Meyermann R; Rapp M; Meisner C; Kortmann RD; Pietsch T; Wiestler OD; Ernemann U; Bamberg M; Reifenberger G; von Deimling A; Weller M
J Clin Oncol; 2009 Dec; 27(35):5874-80. PubMed ID: 19901110
[TBL] [Abstract][Full Text] [Related]
44. Response and progression in recurrent malignant glioma.
Hess KR; Wong ET; Jaeckle KA; Kyritsis AP; Levin VA; Prados MD; Yung WK
Neuro Oncol; 1999 Oct; 1(4):282-8. PubMed ID: 11550320
[TBL] [Abstract][Full Text] [Related]
45. Intra-arterial carboplatin and intravenous etoposide for the treatment of recurrent and progressive non-GBM gliomas.
Newton HB; Slivka MA; Stevens CL; Bourekas EC; Christoforidis GA; Baujan MA; Chakeres DW
J Neurooncol; 2002 Jan; 56(1):79-86. PubMed ID: 11949830
[TBL] [Abstract][Full Text] [Related]
46. Temozolomide and treatment of malignant glioma.
Friedman HS; Kerby T; Calvert H
Clin Cancer Res; 2000 Jul; 6(7):2585-97. PubMed ID: 10914698
[TBL] [Abstract][Full Text] [Related]
47. Toxicity and efficacy of carboplatin and etoposide in conjunction with disruption of the blood-brain tumor barrier in the treatment of intracranial neoplasms.
Williams PC; Henner WD; Roman-Goldstein S; Dahlborg SA; Brummett RE; Tableman M; Dana BW; Neuwelt EA
Neurosurgery; 1995 Jul; 37(1):17-27; discussion 27-8. PubMed ID: 8587686
[TBL] [Abstract][Full Text] [Related]
48. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; Sorarù M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ
Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567
[TBL] [Abstract][Full Text] [Related]
49. Feasibility and usefulness of high-dose chemotherapy (high-dose ifosfamide, carboplatin and etoposide) combined with peripheral blood stem cell transplantation for male germ cell tumor: a single-institute experience.
Hara I; Miyake H; Yamada Y; Yamanaka K; Furukawa J; Kumano M; Takenaka A; Fujisawa M
Anticancer Drugs; 2006 Oct; 17(9):1057-66. PubMed ID: 17001179
[TBL] [Abstract][Full Text] [Related]
50. Pre-irradiation carboplatin and etoposide and accelerated hyperfractionated radiation therapy in patients with high-grade astrocytomas: a phase II study.
Jeremic B; Shibamoto Y; Grujicic D; Milicic B; Stojanovic M; Nikolic N; Dagovic A; Aleksandrovic J
Radiother Oncol; 1999 Apr; 51(1):27-33. PubMed ID: 10386714
[TBL] [Abstract][Full Text] [Related]
51. A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small cell lung cancer: a randomized trial.
Leyvraz S; Pampallona S; Martinelli G; Ploner F; Perey L; Aversa S; Peters S; Brunsvig P; Montes A; Lange A; Yilmaz U; Rosti G;
J Natl Cancer Inst; 2008 Apr; 100(8):533-41. PubMed ID: 18398095
[TBL] [Abstract][Full Text] [Related]
52. Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: the Children's Cancer Group (CCG) experience.
Van Winkle P; Angiolillo A; Krailo M; Cheung YK; Anderson B; Davenport V; Reaman G; Cairo MS
Pediatr Blood Cancer; 2005 Apr; 44(4):338-47. PubMed ID: 15503297
[TBL] [Abstract][Full Text] [Related]
53. High-dose ifosfamide/carboplatin/etoposide with autologous hematopoietic stem cell support: safety and future directions.
Elias AD; Ayash LJ; Wheeler C; Schwartz G; Tepler I; McCauley M; Mazanet R; Schnipper L; Frei E; Antman KH
Semin Oncol; 1994 Oct; 21(5 Suppl 12):83-5. PubMed ID: 7992072
[TBL] [Abstract][Full Text] [Related]
54. Carboplatin and etoposide for recurrent malignant glioma: one department's experience.
Stein ME; Tzuk-Shina Z; Ravkin A; Drumea K; Goldsher D
Am J Clin Oncol; 1998 Apr; 21(2):215-6. PubMed ID: 9537216
[No Abstract] [Full Text] [Related]
55. Outcome of pediatric recurrent and refractory malignant solid tumors following ifosfamide/carboplatin/etoposide (ICE): A phase II study in a pediatric oncology centre in Brazil.
Loss JF; Santos PP; Leone LD; Brunetto AL
Pediatr Blood Cancer; 2004 Feb; 42(2):139-44. PubMed ID: 14752877
[TBL] [Abstract][Full Text] [Related]
56. Paclitaxel plus Ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors.
Kondagunta GV; Bacik J; Sheinfeld J; Bajorin D; Bains M; Reich L; Deluca J; Budnick A; Ishill N; Mazumdar M; Bosl GJ; Motzer RJ
J Clin Oncol; 2007 Jan; 25(1):85-90. PubMed ID: 17194908
[TBL] [Abstract][Full Text] [Related]
57. Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
Raizer JJ; Malkin MG; Kleber M; Abrey LE
Neuro Oncol; 2004 Jul; 6(3):247-52. PubMed ID: 15279717
[TBL] [Abstract][Full Text] [Related]
58. Pilot study of ambulatory infusional delivery of a multidrug regimen: ifosfamide, carboplatin and etoposide (ICE).
Lokich J; Anderson N; Moore C; Bern M; Coco F; Dow E
J Infus Chemother; 1996; 6(1):39-42. PubMed ID: 8748006
[TBL] [Abstract][Full Text] [Related]
59. [Effectiveness of DeVIC chemotherapy for recurrent primary central nervous system lymphoma].
Takasu S; Wakabayashi T; Kajita Y; Hatano N; Hatano H; Usui T; Kinoshita T; Yoshida J
No Shinkei Geka; 2000 Sep; 28(9):789-94. PubMed ID: 11025878
[TBL] [Abstract][Full Text] [Related]
60. Carboplatin and etoposide combined with bevacizumab for the treatment of recurrent glioblastoma multiforme.
Francesconi AB; Dupre S; Matos M; Martin D; Hughes BG; Wyld DK; Lickliter JD
J Clin Neurosci; 2010 Aug; 17(8):970-4. PubMed ID: 20541421
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]